Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

A multicentre audit of HDR/PDR brachytherapy absolute dosimetry in association with the INTERLACE trial (NCT015662405).

Díez P, Aird EGA, Sander T, Gouldstone CA, Sharpe PHG, Lee CD, Lowe G, Thomas RAS, Simnor T, Bownes P, Bidmead M, Gandon L, Eaton D, Palmer AL.

Phys Med Biol. 2017 Nov 9;62(23):8832-8849. doi: 10.1088/1361-6560/aa91a9.

PMID:
28984277
2.

Radiotherapy dosimetry audit: three decades of improving standards and accuracy in UK clinical practice and trials.

Clark CH, Aird EG, Bolton S, Miles EA, Nisbet A, Snaith JA, Thomas RA, Venables K, Thwaites DI.

Br J Radiol. 2015;88(1055):20150251. doi: 10.1259/bjr.20150251. Epub 2015 Sep 2.

3.

Radiation therapy quality assurance in clinical trials--Global Harmonisation Group.

Melidis C, Bosch WR, Izewska J, Fidarova E, Zubizarreta E, Ishikura S, Followill D, Galvin J, Xiao Y, Ebert MA, Kron T, Clark CH, Miles EA, Aird EG, Weber DC, Ulin K, Verellen D, Hurkmans CW.

Radiother Oncol. 2014 Jun;111(3):327-9. doi: 10.1016/j.radonc.2014.03.023. Epub 2014 May 8. No abstract available.

4.

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.

Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, Aird EG, Bottomley D, Huddart RA, Jose CC, Matthews JH, Millar JL, Murphy C, Russell JM, Scrase CD, Parmar MK, Sydes MR.

Lancet Oncol. 2014 Apr;15(4):464-73. doi: 10.1016/S1470-2045(14)70040-3. Epub 2014 Feb 26.

5.

The IPEM code of practice for determination of the reference air kerma rate for HDR (192)Ir brachytherapy sources based on the NPL air kerma standard.

Bidmead AM, Sander T, Locks SM, Lee CD, Aird EG, Nutbrown RF, Flynn A; IPEM Working Party.

Phys Med Biol. 2010 Jun 7;55(11):3145-59. doi: 10.1088/0031-9155/55/11/011. Epub 2010 May 17.

PMID:
20479510
6.

Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials.

Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR; START Trial Management Group.

Lancet Oncol. 2010 Mar;11(3):231-40. doi: 10.1016/S1470-2045(09)70382-1. Epub 2010 Feb 6.

7.

Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397.

Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM, Critchley H, Evans PM, Gianolini S, Mayles WP, Moore AR, Sánchez-Nieto B, Partridge M, Sydes MR, Webb S, Dearnaley DP.

Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):747-54. doi: 10.1016/j.ijrobp.2009.02.025. Epub 2009 Jun 18.

PMID:
19540054
8.

Dosimetry and field matching for radiotherapy to the breast and supraclavicular fossa.

Miles EA, Venables K, Hoskin PJ, Aird EG; START Trial Management Group.

Radiother Oncol. 2009 Apr;91(1):42-8. doi: 10.1016/j.radonc.2008.11.016. Epub 2009 Feb 3.

PMID:
19195731
9.

The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.

START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR.

Lancet Oncol. 2008 Apr;9(4):331-41. doi: 10.1016/S1470-2045(08)70077-9. Epub 2008 Mar 19.

10.

The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.

START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR.

Lancet. 2008 Mar 29;371(9618):1098-107. doi: 10.1016/S0140-6736(08)60348-7. Epub 2008 Mar 19.

12.

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.

Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens RJ, Syndikus I, Parmar MK; RT01 collaborators.

Lancet Oncol. 2007 Jun;8(6):475-87.

PMID:
17482880
13.

What is the optimum breast plan: a study based on the START trial plans.

Venables K, Miles EA, Aird EG, Hoskin PJ.

Br J Radiol. 2006 Sep;79(945):734-9.

PMID:
16940374
14.

A versatile phantom for quality assurance in the UK Medical Research Council (MRC) RT01 trial (ISRCTN47772397) in conformal radiotherapy for prostate cancer.

Moore AR, Warrington AP, Aird EG, Bidmead AM, Dearnaley DP.

Radiother Oncol. 2006 Jul;80(1):82-5. Epub 2006 Jul 7.

PMID:
16828908
15.

Verification films: a study of the daily and weekly reproducibility of breast patient set-up in the START trial.

Venables K, Miles EA, Hoskin PJ, Aird EG; START.

Clin Oncol (R Coll Radiol). 2005 Aug;17(5):337-42.

PMID:
16097564
17.

Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397).

Mayles WP, Moore AR, Aird EG, Bidmead AM, Dearnaley DP, Griffiths SE, Warrington AP; RT01 collaborators.

Radiother Oncol. 2004 Nov;73(2):199-207.

PMID:
15622611
18.

Second cancer risk, concomitant exposures and IRMER(2000).

Aird EG.

Br J Radiol. 2004 Dec;77(924):983-5. No abstract available.

PMID:
15569638
19.

Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer.

Sydes MR, Stephens RJ, Moore AR, Aird EG, Bidmead AM, Fallowfield LJ, Graham J, Griffiths S, Mayles WP, McGuire A, Stanley S, Warrington AP, Dearnaley DP; RT01 collaborators.

Radiother Oncol. 2004 Aug;72(2):199-211.

PMID:
15297138
20.

The use of in vivo thermoluminescent dosimeters in the quality assurance programme for the START breast fractionation trial.

Venables K, Miles EA, Aird EG, Hoskin PJ; START Trial Management Group.

Radiother Oncol. 2004 Jun;71(3):303-10.

PMID:
15172146

Supplemental Content

Loading ...
Support Center